Antibodies to donor HLA antigens are a barrier to solid organ transplant and can significantly reduce graft survival if they develop posttransplant. 1 While advances in antibody detection technology have provided better assessment of HLA antibody specificities, these assays are semiquantitative at best and-when used in isolation-do not provide sufficient guidance for treatment protocols. Currently, the ability to predict or monitor the efficacy of HLA antibody-removal therapies is deficient. We previously reported that titration studies are a consistent and accurate means of assessing antibody strength. To test whether titration studies can also predict which patients are better candidates for desensitization, we studied 
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Johns Hopkins assays for antibody quantitation determined that this application is "confounded by issues affecting assay reproducibility." 3 Therefore, the ability to predict which antibodies will respond sufficiently to desensitization strategies, as well as the use of SAB monitoring as an endpoint for clinical trials of novel desensitization agents, is compromised.
Antibody-removal therapies are required in 2 different clinical scenarios: (1) pretransplant to permit a transplant with a donor to whom a patient has an unacceptable level of donor-specific antibodies (DSAs) and (2) treatment of antibody-mediated rejection (AMR).
In both circumstances, it would be beneficial to gauge the strength of the DSA to guide the selection of the most practical antibody-removal approach, as well as to predict the likelihood of effectively removing the DSA. Moreover, in cases of desensitization before a living donor transplant, it would be useful to accurately predict the total time required for treatment in order to schedule the operating room time for surgery.
Several factors are known to affect the results obtained with SAB assays, including the presence of inhibitory factors in patient serum, 4 as well as saturation of the HLA antigens attached to the beads when antibody levels are extremely high. 5 We previously reported that dilution studies can overcome both of these limitations and provide a more consistent and accurate metric for assessing antibody strength compared with testing undiluted serum with the commercially available IgG or C1q assays. 6 To further analyze whether there is a relationship between reduction in antibody titer (ie, strength) and the treatment protocol used to reduce these antibodies, we retrospectively studied a multicenter cohort of patients who were desensitized before transplant with the use of a center-specific empirical protocol. We aimed to determine if antibody strength quantitation by titration can guide decisions regarding candidacy for desensitization and estimate the amount of treatment needed.
| MATERIAL S AND ME THODS
| Study population and treatment
Patient demographics are shown in Table 1 
Cycles of treatment
Additional details
Cedars-Sinai 
| HLA antibody testing and titration
Serum collected from patients before and after the completion of 
| Statistical analysis
Best-fit lines ( Figure 1 ) were generated by using nonlinear regression models performed with GraphPad Prism (GraphPad Software, San 
| RE SULTS
| Linear relationship exists between initial plasmapheresis/IVIg cycles and antibody titer reduction
Reductions in HLA antibody titers were plotted based on the num- 
| HLA antibody response to plasmapheresis/ IVIg desensitization therapy is similar across all loci
Given the current thought that antibodies to HLA class II antigens, and especially those against HLA-DQ, are less responsive to antibody-removal therapy, 7-11 we sought to compare log2 titer reduction across different loci. For each antibody specificity, a "per-cycle titer reduction" was calculated based on the number of treatment cycles the corresponding patient received. As seen in Figure 2 and 
| Saturation of beads in patients with hightiter antibody prevents adequate quantification of antibody response to removal therapies using MFI
We and others have previously shown that the strength of high-titer antibodies can be underappreciated due to saturation of the target antigen on the beads. 2, 5, 6, 12, 13 In other words, once all the cognate HLA antigen present on the beads has been bound, any excess antibody cannot be "flagged" by the detection/secondary antibody and thus will not be marked by fluorescence (ie, not considered 
| Initial antibody strength can guide the selection of candidates for successful desensitization
To orchestrate a successful graft outcome, DSA levels should be maintained at a fairly low level but do not have to be fully eliminated. The threshold to be crossed should be determined by each center. For this particular analysis, we assumed that DSA levels at the time of transplant should be at a titer of <1:16, which, in our experience, corresponds to negative or weakly positive flow cytometric crossmatch results. Figure S2 shows reduction of antibody titer after 3, 5, 9, or 14 cycles of treatment. While antibodies with a pretreatment titer of up to 1:512 could effectively be lowered to a transplantable level posttreatment, those antibodies at a titer of ≥1:512 could not reliably be reduced to this level despite as many as 14 cycles of treatment. These data suggest that titration studies can be used before the initiation of therapy to predict whether a particular DSA is likely to be successfully reduced by plasmapheresis/IVIg desensitization to a center-specific transplantable level. In addition, for those patients who are likely to respond to therapy, titration can provide a rough estimate of the number of cycles needed to remove antibodies to a transplantable level.
| Titration studies can be applied to other desensitization strategies
Finally, to assess whether titration studies could be used to measure the effect of desensitization with other therapeutic modalities, we studied 9 additional patients. These adult patients were treated at Cedars-Sinai Medical Center using 2 high doses (2 g/kg)
of IVIg with a single dose of rituximab (375 mg/m 2 ) "sandwiched" between the IVIg doses. Figure 4A shows the effect of treatment on ΔMFI in these patients, with some values decreasing and others increasing. Figure 4B , on the other hand, clearly indicates that using titer metrics to assess antibody strength reduction demonstrates a more consistent reduction in antibody strength, with an average of 1.8 log2 titer reduction following treatment. These data suggest that titration studies are a widely applicable metric that can assist in the determination of treatment efficacy for multiple approaches. 
| D ISCUSS I ON
The ability to detect HLA antibodies was revolutionized by the introduction of solid phase testing, specifically the SAB assay on the Luminex platform. Initially, the increased sensitivity of the assay was met with skepticism, with concern that these tests would unnecessarily limit access to transplant for patients with SAB-positive, cytotoxicity-negative DSAs. 13 As evidence regarding the clinical relevance of these antibodies was gathered and published, 14- 18 MFI units were also used in an attempt to risk-stratify patients, whether pretransplant or at the time of AMR, and later as a tool to monitor efficacy of antibody-removal treatment protocols.
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The use of MFI values was extended beyond its intended use and indeed beyond its capabilities, as highlighted by an FDA workshop dedicated to better understand the process, diagnosis, and treatment of AMR, 3 and by others. Therefore, there is a pressing need for a standardized approach that can assess individual HLA antibody specificities and strength during treatment at any time pretransplant or posttransplant.
Our previous study in patients undergoing desensitization protocols demonstrated that monitoring the reduction of antibody strength through titration studies showed relatively uniform patterns compared with undiluted IgG-MFI and C1q-MFI. 27 We further speculated that titration studies could be used as a quantitative measure to monitor antibody-removal therapies. In this study, we partnered with 2 additional centers that use desensitization to Fc receptor-mediated recycling. 28 Studies investigating the effects of plasmapheresis on antibody synthesis by plasma cells are conflicting, with some studies suggesting that plasmapheresis may lead to a homeostatic "rebound" in antibody synthesis. 29, 30 However, other researchers have found no evidence of this phenomenon, 31, 32 with one study suggesting that the increases in antibody levels after plasmapheresis are due to lower rates of catabolism rather than to an increase in synthesis. 33 Furthermore, the mechanism by which IVIg reduces alloantibody levels is still a subject of intense debate. 34 We have not measured the levels of antibody synthesis in individual patients after treatment; however, our data suggest that there is a limit to the linear response to plasmapheresis/IVIg treatment, followed by a decline in efficacy. Specifically, in our experience, patients with antibodies at an initial titer of >1:512 could not be reduced to the goal of a negative lymphocyte crossmatch, corresponding to a titer of 1:16, despite a significant increase in the number of treatment cycles. Our rationale in choosing this goal is to minimize the rate of AMR during the first year posttransplant. While other centers may choose a different antibody strength goal at the time of transplant, the titration scheme provided here can be applied regardless, using center-specific criteria. Therefore, using titration studies, it is possi- (Table S1) , it stands to reason that they would show a slightly lower average reduction per treatment cycle and not necessarily that these antibodies are more difficult to remove. This conjecture needs to be further investigated. Importantly, in our cohort, antibodies to HLA-DQ targets were as responsive to treatment as antibodies in HLA-B, -C, -DRB1, and -DRB3/4/5 loci. While this observation seems to contradict current perception, we believe there is a simple explanation.
We previously demonstrated that there is a significant saturation effect that prohibits the accurate measurement of antibody strength over a titer of 1:128-1:512. 5, 27 We also demonstrated that antibodies against HLA-DQ are most prone to this saturation effect. We believe that while HLA-DQ antibodies respond similarly to treatment as antibodies against other loci, reduction in strength may be missed by MFI if both pretreatment and posttreatment antibodies saturate the beads in undiluted serum. The example provided in Figure 1 clearly illustrates this phenomenon, and Figure 3 demonstrates that saturation most often occurs at an antibody titer of >1:128.
A common and valid criticism to using titer metrics is the additional cost associated with performing dilution studies. We submit that a detailed titration scheme (ie, serial 1:4 dilutions as presented in our studies) is required only to define relevant clinical ranges. Once those are defined, a coarser scale can be applied to inform treatment decisions. For example, the use of 8× dilution (neat, 1:64, 1:512, and 1:4096) would separate those antibodies that will quickly respond to treatment from those that are at the effective limit of the treatment, those that are likely to require combination therapy, and those that are likely untreatable and should be avoided if possible. Larger studies are required to define a clinically useful titration schema to support desensitization and AMR treatment decisions and to determine the curve of efficiency for plasmapheresis/IVIg protocols. Another important consideration that can affect the patients' response to treatment may be the original mode of sensitization, which has been shown to affect the characteristics of the antibody response to HLA antigens. 36 Because of the small size of this cohort and its retrospective nature, we were unable to perform analysis based on these factors, but we believe this should be an important area of focus for future prospective studies of desensitization treatment. In addition,
while a formal analysis of graft outcomes for the Johns Hopkins and
Northwestern patients was not performed, we can report that approximately 50% of the patients who had DSA titers of <1:128 before treatment did not experience any rejection within the first year.
Conversely, all of the patients with pretreatment DSA titers of >1:128 had rejection episodes within 12 months, despite receiving on average more cycles of treatment pretransplant and posttransplant.
In summary, our results demonstrate that antibody titration studies are able to serve as a quantitative measure of antibody strength as well as a tool to measure efficacy of pretransplant desensitization therapy. These data can also be used to extrapolate and predict the number of treatment cycles needed to lower a particular DSA to a transplantable level. The ability to infer a range of successful treatment can help determine which patients are good candidates for desensitization given a particular donor and DSA titer. Having this information before initiating therapy can reduce the added risk, cost, time, and patient discomfort associated with futile treatment.
Titration studies can also assist in the evaluation of novel therapies, as they can provide more accurate information regarding the antibody strength in a given cohort and allow for the comparison of results across different centers and studies.
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